Enriqueta Felip is the Head of the Thoracic and Head and Neck Cancer Unit within the Oncology Department of Vall d'Hebron Hospital, Barcelona, Spain. Professor Felip is in charge of thoracic malignancy management, and is responsible for thoracic cancer trials undertaken by the Oncology Department. Current research lines include the optimization of chemotherapy in early-stage disease, evaluation of new agents and therapies, research into novel pharmacogenomic approaches, the integration of immunotherapeutic approaches in the treatment of lung cancer patients, and the elucidation of potential mechanisms of resistance to tyrosine-kinase inhibitors. Dr Felip received her medical degree from the UAB, where she also completed her PhD studies in medical oncology. She has been Associate Professor at the Autonomous University of Barcelona (UAB) from 2010 to May 2019. She is nowadays, Professor of Medicine at the Universitat de Vic (UVicc-UCC). She is involved in the training of medical students, residents and particularly in mentoring fellows. Dr Felip is currently a member of the Spanish Lung Cancer Group (SLCG) and the Spanish Society of Medical Oncology (SEOM). In October 2019, Dr. Felip was elected SEOM Vice-President for the following years 2019-2021. Dr. Felip is also member of the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), and the International Association for the Study of Lung Cancer (IASLC). She is nowadays member of the Board of Directors of IASLC (2017-2021). Dr. Felip has been Co-chair of the 20th WCLC Congress that took place last September 2019 in Barcelona. Dr. Felip receives the 1st ESMO Women for Oncology Award in 2015. Dr. Felip is now President of the Oncology Comission at Vall d’Hebron University Hospital and she is as member of the Scientific Advisory Committee of the Parc Tauli? Sabadell Hospital. Dr Felip has been involved in several initiatives with scientific organizations, among them, as Subject Editor of Guidelines Working group ESMO Minimum Clinical Recommendations in lung cancer and Coordinator of the 1st ESMO Consensus Conference in lung cancer. Dr Felip is at present a member of the scientific committee of the SLCG. Dr Felip is also author of many peer-reviewed articles and book chapters relating to the field of thoracic malignancies.

I am a Spanish medical oncologist, working in Thoracic Oncology. I finished my training in medical oncology in Salamanca in 2011, and then I moved to Madrid where I worked during 4 years. Between 2015 and 2020 I have been working in Gustave Roussy (France) initially as Translational Research Fellow in lung cancer Immunoncology (2015-2016), followed by a 2 years period of Clinical Fellow in the Thoracic Oncology Group (2016-2018). Between November 2018 and January 2020 I joined the Precision Medicine Group at Gustave Roussy. In 2018, I completed my PhD project about the impact of radon gas in certain molecular subtypes of lung cancer. From February 2020, I am working in the Hospital Clinic (Barcelona, Spain), and I have also joined the Translational Genomics and Targeted Therapeutics Group, led by Dr. Aleix Prat (IDIBAPS, Barcelona), as Translational Researcher. I am involved in several clinical and translational research projects focus on 3 main areas: a) biomarkers for immunotherapy, b) precision medicine, focused on liquid biopsy, and c) molecular epidemiology (radon gas in lung cancer).

Dr. Federico Cappuzzo has been the Director of Medical Oncology at the National Cancer Institute Regina Elena in Rome. He is a member of the Italian Association in Medical Oncology (AIOM), European Society for Medical Oncology (ESMO), American Society Clinical Oncology (ASCO) and International Association for the Study of Lung Cancer (IASCL) and since 2006 as a Member of the editorial board of Lung Cancer. From 2013 to 2017 he was the Chairman of the Educational Committee of IASLC. In 2006, 2009 and 2012 he received research grants from the Italian Association for Cancer Research (AIRC) on targeted therapies in lung cancer and is the author of more than 250 papers in peer-review journals, mainly in translational research in lung cancer.

Joachim Aerts is head of department of Pulmonary Medicine of Erasmus MC Rotterdam. He is a renown expert in fundamental, translational and clinical immuno-oncology research, with a strong focus on lung cancer and mesothelioma. He has authored >200 publications and is PI of studies funded by e.g. EU Horizon2020 and ZonMw.

Martin Reck, MD, PhD, is head of the Department of Thoracic Oncology and head of the Clinical Trial Department in the Department of Thoracic Oncology at the Lung Clinic Grosshansdorf, Germany. He is also Principal Investigator in the Airway Research Center North (ARCN), which is a member of the German Centre for Lung Research (DZL). Dr Reck has been a Principal Investigator (PI) in various clinical trials since 1993. His main interests are new medical treatments of thoracic malignancies as well as translational research related to predictive markers. A particular focus of his work has been attributed to the clinical development of antiangiogenic compounds. Recently he also has been deeply involved in several key trials with immunotherapies including ipilimumab, PD-1 and PDL-1 antibodies and other agents. As part of this activity he has been the principal investigator of the Keynote 24 trial investigating monotherapy with Pembrolizumab against platinum based chemotherapy in untreated patients with advanced PDL-1 expressing NSCLC (TPS =/> 50%), IMpower 150 trial and the CheckMate 9LA trial, which evaluated the combination of Nivolumab and Ipilimumab together with a short chemotherapy. Furthermore he has served on various Global Trial Steering Committees. Besides the European Society of Medical Oncology (ESMO) Dr Reck is member of the International Association for the study of Lung Cancer (IASLC), the American society of Medical Oncology (ASCO), the German Working Group for Lung Cancer, the German Cancer Society (DKG) and the German Society of Pulmonology (DGP). He has published papers in numerous peer-reviewed journals and is member of the editorial board of Journal of Thoracic Oncology, Annals of Oncology and Lung Cancer.

Simon Ekman, MD, PhD, is a Senior Consultant, Associate Professor in Oncology and Head of lung cancer research at the Karolinska University Hospital and Karolinska Institutet in Stockholm, Sweden.

Dr Jordi Remon, MD, PhD is medical oncologist in Barcelona from 2005. Currently Dr Remon is full time cancer specialist at CIOCC Barcelona – HM Delfos in Barcelona, Spain, dealing with patients with thoracic malignancies. His special interests are in the field of personalised therapeutic approaches, immunotherapy, as well as thymic malignancies.

Since 2018, Dr Alessandra Curioni has served as Head of Medical Thoracic Oncology at the University Hospital Zurich (USZ), where she originally trained. Dr Curioni also chairs the USZ Expert Group in Immuno-Oncology, and leads a translational research group specialising in topics including immunotherapy resistance and novel combination treatments for thoracic malignancies. Outside USZ, Dr Curioni directs the Lung Cancer Program at the European School of Oncology (ESO) and is a member of the ESMO faculty for Investigational Immunotherapy. She is a senior author on a number of phase III trials in lung cancer and mesothelioma.

Dr. Noemi Reguart earned her Medical Degree from the University of Medicine Lleida, in Spain. She completed her postgraduate training and fellowship in the Oncology Department at Hospital Clinic Barcelona. Dr. Reguart gained a PhD focusing on molecular lung cancer biology at the General Thoracic Surgery and Oncology Laboratory, at the University of California San Francisco (UCSF). She has practiced as a Consultant Oncologist at the Department of Medical Oncology in Hospital Clinic Barcelona since 2008. She is a Clinical Professor at the University of Barcelona, deeply committed to under- and postgraduate teaching. Most recently Dr. Reguart has been designated the Director of the Thoracic Oncology Unit at the Hospital Clínic. Throughout her career, Dr. Reguart has shown her interest in addressing lung cancer. In addition to clinical practice and patient care, she also conducts basic research with a special interest in lung cancer biomarkers and the identification of predictors of therapy response at the August Pi i Sunyer Biomedical Research Institute (IDIBAPS). She has always maintained an active research interest in her own laboratory as well as through several national and international collaborations. Dr. Reguart is an active member of several international lung cancer organizations including ESMO, IASLC, SLCG, and EORTC, and the author of several scientific publications.